PLAtelet function in Critical Illness and liver Disease (PLACID)
Liver disease, critical illness, platelet function
This is an observational study, there are no interventions. The following is a brief summary of our methodologies. A total of 30 patients will be recruited for this study from the ICU at the Royal Berkshire Hospital. Up to 5, 50 ml blood samples will be taken from venous and/or arterial access during their stay in the ICU. An additional sample (not exceeding 50 ml) may also be requested when the patient is recovering on a ward. Molecular analysis will also be performed on the samples of recalled patients to identify molecular differences in platelet function between the groups. Several tests will be performed to understand which stage/ stages during platelet activation are affected in patients with liver disease as part of their critical illness. The tests performed will be carried out in an order which will make the best use of the blood samples taken from each individual participant.
Current participant inclusion criteria as of 24/05/2024: 1. Admitted to ICU at the Royal Berkshire Hospital 2. Aged 18 years old and above 3. Evidence of established liver disease, or acute liver dysfunction related to underlying illness, as determined by the clinicians caring for the patient at the time of eligibility assessment. Previous participant inclusion criteria: 1. Known liver disease or 2. Acute liver dysfunction
1. Patients on P2Y12 inhibitors (including clopidogrel, ticagrelor and prasugrel) 2. Patients on treatment-dose anticoagulation, including warfarin or novel anticoagulant drugs 3. Patients under 18 years of age 4. Active or recent malignancy (< 1 year) or on active treatment